331 related articles for article (PubMed ID: 34944730)
1. Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem.
Le Garf S; Nègre V; Anty R; Gual P
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944730
[TBL] [Abstract][Full Text] [Related]
2. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD).
Roeb E
Visc Med; 2021 Aug; 37(4):273-280. PubMed ID: 34540943
[TBL] [Abstract][Full Text] [Related]
3. Innate immunity and nonalcoholic fatty liver disease.
Kountouras J; Kazakos E; Kyrailidi F; Polyzos SA; Zavos C; Arapoglou S; Boziki M; Mouratidou MC; Tzitiridou-Chatzopoulou M; Chatzopoulos D; Doulberis M; Papaefthymiou A; Vardaka E
Ann Gastroenterol; 2023; 36(3):244-256. PubMed ID: 37144011
[TBL] [Abstract][Full Text] [Related]
4. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies.
Habibullah M; Jemmieh K; Ouda A; Haider MZ; Malki MI; Elzouki AN
Front Med (Lausanne); 2024; 11():1291501. PubMed ID: 38323033
[TBL] [Abstract][Full Text] [Related]
5. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
Flisiak-Jackiewicz M; Bobrus-Chociej A; Wasilewska N; Lebensztejn DM
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33804296
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease.
Lin H; Zhang X; Li G; Wong GL; Wong VW
J Clin Transl Hepatol; 2021 Dec; 9(6):972-982. PubMed ID: 34966660
[TBL] [Abstract][Full Text] [Related]
7. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
Kjær MB; George J; Kazankov K; Grønbæk H
Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486
[TBL] [Abstract][Full Text] [Related]
8. A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health.
Ramírez-Mejía MM; Díaz-Orozco LE; Barranco-Fragoso B; Méndez-Sánchez N
Med Sci Monit; 2021 Aug; 27():e934134. PubMed ID: 34456329
[TBL] [Abstract][Full Text] [Related]
9. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.
Mărginean CO; Meliț LE; Săsăran MO
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944682
[TBL] [Abstract][Full Text] [Related]
11. Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children.
Rupasinghe K; Hind J; Hegarty R
J Pediatr Gastroenterol Nutr; 2023 Nov; 77(5):583-591. PubMed ID: 37592398
[TBL] [Abstract][Full Text] [Related]
12. The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease.
Kulkarni AV; Sarin SK
Ther Adv Endocrinol Metab; 2023; 14():20420188231178370. PubMed ID: 37323163
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease.
Kaya E; Yilmaz Y
Ther Adv Endocrinol Metab; 2022; 13():20420188221139650. PubMed ID: 36533185
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
[TBL] [Abstract][Full Text] [Related]
15. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
[TBL] [Abstract][Full Text] [Related]
16. MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis.
Segura-Azuara NLÁ; Varela-Chinchilla CD; Trinidad-Calderón PA
Front Med (Lausanne); 2021; 8():774079. PubMed ID: 35096868
[TBL] [Abstract][Full Text] [Related]
17. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.
Gutiérrez-Cuevas J; Santos A; Armendariz-Borunda J
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769060
[TBL] [Abstract][Full Text] [Related]
19. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma.
Khan FZ; Perumpail RB; Wong RJ; Ahmed A
World J Hepatol; 2015 Aug; 7(18):2155-61. PubMed ID: 26328027
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
